ArticleThe Laryngoscope2025
Adjuvant Radiotherapy in pT1-2N0M0 Head and Neck Adenoid Cystic Carcinoma.
Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Adjuvant Radiotherapy in pT1-2N0M0 Head and Neck Adenoid Cystic Carcinoma.The Laryngoscope · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence regarding the indications and survival benefit of adjuvant radiotherapy (aRT) in pT1-2N0M0 head and neck adenoid cystic carcinoma (HNAdCC) is inconclusive. Lower-staged, node-negative HNAdCC therefore represents a rare, moderate-risk disease category with high variation in adjuvant management depending on patient and physician preferences. Our study investigates the impact of aRT on overall survival (OS) in this rare, moderate-risk disease category.
methodsThe 2006 to 2018 National Cancer Database was retrospectively reviewed for patients with pT1-2N0M0 HNAdCC. Multivariable binary logistic and Cox regression models were implemented.
resultsOf 738 patients satisfying inclusion criteria, 379 (51.4%) underwent aRT. Oral cavity primary site (aOR 0.64, 95% CI 0.43-0.96) was associated with lower odds of undergoing aRT (p < 0.05); neck dissection (aOR 1.58, 95% CI 1.09-2.28) and PSM (aOR 1.84, 95% CI 1.30-2.60) were associated with higher odds of undergoing aRT (p < 0.025). Patients undergoing aRT had higher 5-year (94% vs. 86%) and 10-year OS (85% vs. 73%) than those not undergoing aRT (p < 0.001). Adjusting for patient demographics, pathologic features, and treatment, age at diagnosis (aHR 1.05, 95% CI 1.02-1.08, p < 0.001) was associated with worse OS; aRT (aHR 0.30, 95% CI 0.13-0.69, p = 0.005) was associated with higher OS.
conclusionApproximately half of patients with pT1-2N0M0 HNAdCC did not undergo aRT, highlighting a possible deviation from evidence-based recommendations and an opportunity for quality improvement in the multidisciplinary care of patients. aRT was associated with higher 5-year and 10-year OS, suggesting that patients with lower-staged, node-negative HNAdCC should be offered aRT to optimize long-term survival. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.